Patent application number | Description | Published |
20100317038 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 12-16-2010 |
20110171645 | METHODS OF DIAGNOSING ACUTE CARDIAC ALLOGRAFT REJECTION - The present invention relates to methods of diagnosing acute rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, metabolite profiling, or alloreactive T-cell genomic expression profiling, | 07-14-2011 |
20110189680 | Methods of Diagnosing Rejection of a Kidney Allograft Using Genomic or Proteomic Expression Profiling - A method of determining the acute allograft rejection status of a subject, the method comprising the steps of: determining the nucleic acid expression profile of one or more than one nucleic acid markers, or one or more than one proteomic markers in a biological sample from the subject; comparing the expression profile of the one or more than one nucleic acid markers to a control profile; and determining whether the expression level of the one or more than one nucleic acid markers is increased relative to the control profile, wherein the increase of the one or more than one nucleic acid markers is indicative of the acute rejection status of the subject. | 08-04-2011 |
20110190151 | METHODS OF DIAGNOSING CHRONIC CARDIAC ALLOGRAFT REJECTION - The present invention relates to methods of diagnosing chronic rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, or a combination of genomic and proteomic expression profiling. | 08-04-2011 |
20110229546 | TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS - A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided. | 09-22-2011 |
20130323749 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic Inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 12-05-2013 |
20140255953 | GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin. | 09-11-2014 |
20150133326 | BIOMARKERS FOR RECOVERED HEART FUNCTION - Disclosed herein is a method for determining recovered heart function in a subject based in the biomarker ceruloplasmin in patient samples. Also disclosed are computer systems, kits and software. | 05-14-2015 |